Leucovorin

Leucovorin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Pancreatic Cancer、Metastatic Pancreatic Cancer、Metastatic Pancreatic Adenocarcinoma、Solid Tumor。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Leucovorin 研究

• Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

  I 期 / II 期招募中美国BrazilChile中国NCT06780111

• Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

  I 期 / II 期招募中美国NCT06483555

• Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

  II 期招募中中国NCT06121700

• Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study

  II 期招募中中国NCT07806292

• Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

  II 期招募中中国NCT06928584

• Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

  III 期招募中意大利NCT06509126

• Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU

  II 期招募中中国NCT07391618

• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  III 期招募中美国澳大利亚加拿大新西兰NCT03959085

• The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

  IV 期招募中中国NCT06368063

• sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

  II 期招募中美国NCT05332002

• Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.

  III 期招募中中国NCT07595276

• DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

  III 期招募中荷兰NCT06275958

• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  I 期招募中美国加拿大中国法国NCT06131840

• Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors

  II 期招募中中国NCT07337460

• DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer

  II 期招募中法国NCT06757244

• Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial

  II 期招募中中国NCT07106034

• A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

  III 期招募中中国NCT03303495

• Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC

  III 期招募中中国NCT06041477

• A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  III 期招募中美国Argentina奥地利BrazilNCT07043400

• Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

  I 期 / II 期招募中中国NCT05319639

• Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  III 期招募中美国加拿大NCT06958328

• Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

  II 期招募中中国NCT06184698

• New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

  II 期招募中中国NCT07559760

• A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

  II 期招募中美国澳大利亚比利时BrazilNCT07415031

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。